Status:
UNKNOWN
Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
Lead Sponsor:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Collaborating Sponsors:
Centro Cardiologico Monzino
Azienda Ospedaliera Niguarda Cà Granda
Conditions:
ST-Elevation Myocardial Infarction
Primary Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In the setting of ST elevation myocardial infarction newer therapies has been recently studied and, following encouraging results, introduced into the clinical practice. Prasugrel showed to be a valid...
Detailed Description
Background: In the setting of STEMI, adjunctive pharmacological therapy plays a key role in the acute management. Along with the clear benefit of mechanical reperfusion strategies, several drugs show...
Eligibility Criteria
Inclusion
- ST elevation myocardial infarction
- No contraindication to primary PCI
Exclusion
- Known intolerance/allergy to one of the study drugs or their components
- Clinical indication to treatment with oral anticoagulant, including use of warfarin or dabigatran or other oral anticoagulant agents
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT01158846
Start Date
August 1 2010
End Date
June 1 2011
Last Update
July 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico S. Ambrogio
Milan, Italy, 20149